Supersaturated Oxygen Therapy Study to Assess Utility, Cost-effectiveness
The first patient has enrolled in a study to assess the clinical utility and cost-effectiveness of Zoll TherOx SuperSaturated Oxygen (SSO2) Therapy.
Tag: Zoll TherOx SSO2 Therapy
All
Latest
Supersaturated Oxygen Therapy Study to Assess Utility, Cost-effectiveness
The first patient has enrolled in a study to assess the clinical utility and cost-effectiveness of Zoll TherOx SuperSaturated Oxygen (SSO2) Therapy.
Read More
Premier Inc Signs Purchase Agreement for Zoll TherOx SSO2 Therapy
Zoll Medical Corp’s TherOx SuperSaturated Oxygen (SSO2) Therapy has been awarded a group purchasing agreement for Diagnostic and Interventional Cardiology Catheters (DIC) with Premier Inc, effective as of July 1, 2022.
Read More
Zoll to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange
Zoll will exhibit its TherOx SuperSaturated Oxygen (SSO2) Therapy at the Vizient Innovative Technology Exchange on October 17.
Read More
Supersaturated Oxygen Therapy Studied for LAD-STEMI Patients
The first patient has enrolled in a post-approval study further evaluating TherOx SuperSaturated Oxygen (SSO2) Therapy for the treatment of LAD-STEMI, the most severe form of heart attack.
Read More
CMS Issues New ICD-10 Code for Zoll TherOx SSO2 Therapy
The Centers for Medicare & Medicaid Services issued a new ICD-10-PCS code for TherOx SuperSaturated Oxygen (SSO2) Therapy, according to Zoll Medical Corp.
Read More
AMA Issues New CPT Code for Zoll TherOx SSO2 Therapy
The American Medical Association (AMA) CPT Editorial Panel issued a new Category III CPT code for the TherOx SuperSaturated Oxygen (SSO2) Therapy, according to Zoll Medical Corp.
Read More
FDA Green-lights Supersaturated Oxygen Therapy Study for Shock Patients
The US FDA approved an investigational device exemption (IDE) for a study evaluating the use of TherOx SuperSaturated Oxygen (SSO2) Therapy in patients presenting with STEMI and cardiogenic shock.
Read More
Zoll Receives CE Mark for SuperSaturated Oxygen Therapy
Zoll Medical Corp received CE Mark approval for the TherOx SuperSaturated Oxygen (SSO2) Therapy System in Europe.
Read More
FDA Approves Updated SSO2 Therapy for LAD-STEMI Patients
The US FDA approved Zoll Medical’s second-generation TherOx SuperSaturated Oxygen (SSO2) Therapy System for patients suffering LAD-STEMI.
Read More
Scripps La Jolla First US Healthcare System to Treat LAD-STEMI Patients with SSO2
Scripps Memorial Hospital La Jolla (San Diego) treated its first LAD-STEMI patient with Zoll’s TherOx SuperSaturated Oxygen (SSO2) Therapy.
Read More
Zoll Acquires TherOx Inc’s Supersaturated Oxygen Therapy
Zoll Medical Corp has acquired TherOx Inc, whose SuperSaturated Oxygen (SSO2) Therapy System was recently approved by the FDA to treat acute myocardial infarction patients.
Read More